Pharmafile Logo

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.

Biosimilars medicines, the follow-on “generics” to biologics which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems. 

Download and read the complimentary whitepaper at http://bit.ly/1Gmknh7  

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Article: Spotlight on Mexico

Healthcare under AMLO – One year on

News: Mandira Kar joins London Headquarters as Qualitative Research Director

Research Partnership are delighted to announce that Mandira Kar has joined as a Qualitative Research Director. Mandira is an expert in ethnography with over 15 years’ experience in market research,...

Announcing a change of leadership at the US Philadelphia office

Research Partnership’s Philadelphia office is announcing a change of leadership from the start of 2020. President Harriet Kozak will be stepping down in order to take retirement at the end...

Article: Market access in Brazil

All eyes on Spinraza

China: How to strategise and win in the world’s fastest changing healthcare market

In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...

Article: Engaging patient advocacy groups

The key to conducting effective rare disease research

Webcast: Harnessing the power of social: How to generate fresh insights for your business using social media listening

Download our third Innovation in #MRX webcast, hosted in partnership with Convosphere, where we discuss how to use social media listening to answer key business questions.Watch here: https://bit.ly/2nM0xvj

Article: Like, Like, Like: Harnessing the power of social media insights

Given the colossal amount of personal and professional information that we share online, social media channels such as Facebook and Twitter are fast becoming treasure troves of big data. As...

Infographic: China: How to keep up and win in the world’s fastest changing healthcare market

Our latest infographic outlines the changes to the clinical trial process, accelerated drug approval, fast track of rare disease products and access opportunities in China's evolving healthcare environment.Find out more here-...